LMR Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$166M Buy
+180,300
New +$183M 0.37% 24
2025
Q3
Sell
-96,700
Closed -$75.4M 1566
2025
Q2
$75.4M Hold
96,700
0.54% 31
2025
Q1
$79.9M Buy
+96,700
New +$80.5M 0.75% 16
2024
Q1
Sell
-47,000
Closed -$27.4M 1245
2023
Q4
$27.4M Buy
47,000
+22,100
+89% +$12.9M 0.31% 71
2023
Q3
$13.4M Sell
24,900
-155,900
-86% -$80.3M 0.15% 154
2023
Q2
$84.8M Buy
+180,800
New +$75.8M 0.94% 12

Other funds holding LLY

LMR Partners's LLY Position: Q1 2026 in Review

LMR Partners increased its Eli Lilly (LLY) stake by 748% in Q1 2026, buying an estimated $83.6M and bringing the position to 93,539 shares worth $86M. The position accounts for 0.19% of the portfolio, ranked #53.

LMR Partners first reported a position in LLY in Q2 2015 and has held it in 23 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • LMR Partners held 93,539 shares of Eli Lilly worth $86M as of Q1 2026.
  • LMR Partners bought 82,507 Eli Lilly shares in Q1 2026, an estimated $83.6M.
  • Eli Lilly made up 0.19% of LMR Partners's portfolio in Q1 2026, its #53 holding.
  • LMR Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 23 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.